Bringing Promising Breakthroughs Directly to Patients
University Hospitals Seidman Cancer Center partners with Case Western Reserve University School of Medicine to make new discoveries and create advancements in cancer care. This partnership facilitates major, nationally funded research. The research includes clinical trials of new drugs, pioneering techniques and novel devices for cancer diagnosis and treatment.
At any given time physicians and researchers participate in hundreds of clinical trials. Our patients have many opportunities to pursue investigational therapies not available at other institutions.
International Clinical Trial of Lung Cancer Vaccine
UH Seidman Cancer Center is participating in a multicenter, international clinical trial of a new treatment for non small cell lung cancer using the liposome vaccine (L-BLP25). This investigational therapeutic lung cancer vaccine is being used to treat patients with inoperable, stage III non small cell lung cancer.
The vaccine is designed to help the immune system recognize cancer cells and provoke an immune response strong enough to attack and destroy them.
Testing New Drugs for Early Phase Cancers
UH Seidman Cancer Center is one of only 12 cancer centers in the U.S. with access to the new drug pipeline for early phase clinical trials. About 20 percent of our patients are enrolled in clinical trials, as compared to the national average of 4 percent.